Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2013-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.2013.742886PMID 23157681
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase 2 Southwest Oncology Group‐directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas

  2012cited by this paper
• Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

  2011cited by this paper
• Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial

  2011cited by this paper
• A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST).

  2011cited by this paper
• 2010 ASCO annual meeting.

  2010cited by this paper
• Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy.

  2010cited by this paper
• Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

  2009cited by this paper
• Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling

  2008cited by this paper
• Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.

  2008cited by this paper
• The “old drug” dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas

  2008cited by this paper
• Phase II trial of sorafenib in advanced thyroid cancer.

  2008influential reference
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation*

  2005cited by this paper
• Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

  2005cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.

  2002cited by this paper
• High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group.

  1991cited by this paper
• Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas.

  1987cited by this paper

• Targeted therapies for soft tissue sarcomas and desmoid tumors

  2022cites this paper
• Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database

  2022cites this paper
• Molecular targeted therapy for advanced or metastatic soft tissue sarcoma

  2021influential citation
• Optimising extraction of antioxidants from roasted Moringa oleifera Lam. leaves using response surface methodology

  2020cites this paper
• The role of autophagy in age‐related macular degeneration

  2018cites this paper
• Simultaneous determination of phenolic acids and flavonoids in Chenopodium formosanum Koidz. (djulis) by HPLC‐DAD‐ESI–MS/MS

  2017cites this paper
• The polypill in cardiovascular prevention: evidence, limitations and perspective - position paper of the European Society of Hypertension.

  2017cites this paper
• Absence of collagen XVIII in mice causes age-related insufficiency in retinal pigment epithelium proteostasis

  2016cites this paper
• Combination of cytotoxic agents and targeted therapy for the treatment of advanced sarcomas: preclinical background and early clinical development

  2016cites this paper
• A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.

  2015cites this paper
• Targeted therapy in sarcomas other than GIST tumors

  2015cites this paper
• Characterization of the DNA methylation patterns of chemosensitive and chemoresistant human cancer cells: Biological and clinical impact

  2014cites this paper
• Targeted polytherapy in small cell sarcoma and its association with doxorubicin

  2014cites this paper
• Do anti-angiogenic cancer therapies increase risk of significant weight loss?

  2014cites this paper
• Anti-angiogenic therapy, a new player in the field of sarcoma treatment.

  2014cites this paper
• Antiangiogenic approach in soft-tissue sarcomas

  2013cites this paper
• Targeted therapy in soft tissue sarcoma-a novel direction in therapeutics.

  2013cites this paper
• Emerging therapies for sarcoma.

  2013cites this paper
• Oncotargets and Therapy Dovepress Dovepress Diarrhea as Initial Manifestation of Pulmonary Artery Intimal Sarcoma: a Case Report and Literature Review

  year unknowncites this paper